Critical limb ischemia (CLI), defined as ischemic rest pain or nonhealing ulceration due to arterial insufficiency, represents the most severe and limb-threatening manifestation of peripheral artery disease. A major challenge in the optimal treatment of CLI is that multiple specialties participate in the care of this complex patient population. As a result, the care of patients with CLI is often fragmented, and multidisciplinary societal guidelines have not focused specifically on the care of patients with CLI. Furthermore, multidisciplinary care has the potential to improve patient outcomes, as no single medical specialty addresses all the facets of care necessary to reduce cardiovascular and limb-related morbidity in this complex patient population. This review identifies current gaps in the multidisciplinary care of patients with CLI, with a goal toward increasing disease recognition and timely referral, defining important components of CLI treatment teams, establishing options for revascularization strategies, and identifying best practices for wound care post-revascularization.
ShishehborMHWhiteCJGrayBHet al. Critical limb ischemia: an expert statement. J Am Coll Cardiol. 2016;68:2002–2015.
2.
TASC Steering Committee, JaffMRWhiteCJet al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the management of peripheral arterial disease (TASC II). J Endovasc Ther. 2015;22:663–677.
3.
AgarwalSSudKShishehborMH.Nationwide trends of hospital admission and outcomes among critical limb ischemia patients. J Am Coll Cardiol. 2016;67:1901–1913.
4.
SteunenbergSLRaatsJWTe SlaaAet al. Quality of life in patients suffering from critical limb ischemia. Ann Vasc Surg. 2016;36:310–319.
5.
VemulapalliSGreneirMAJonesWSet al. Peripheral arterial testing before lower extremity amputation among Medicare beneficiaries, 2000 to 2010. Circ Cardiovasc Qual Outcomes. 2014;7:142–150.
6.
GoodneyPPTravisLLNallamothuBKet al. Variation in the use of lower extremity vascular procedures for critical limb ischemia. Circ Cardiovasc Qual Outcomes. 2012;5:94–102.
7.
NehlerMRDuvalSDiaoLet al. Epidemiology of peripheral artery disease and critical limb ischemia in an insured national population. J Vasc Surg. 2014;60:686–695.
8.
GoodneyPPHolmanKHenkePKet al. Regional intensity of vascular care and lower extremity amputation rates. J Vasc Surg. 2013;57:1471–1480.
9.
WestinGGArmstrongEJBangHet al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival rates in patients with critical limb ischemia. J Am Coll Cardiol. 2014;63:682–690.
10.
ArmstrongEJChenDCSinghGDet al. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. Vasc Med. 2015;20:237–244.
11.
ArmstrongEJWuJSinghGDet al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg. 2014;60:1565–1571.
12.
ArmstrongEJChenDCWestinGGet al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3:e000697.
13.
DuvalSKeoHHOldenburgNCet al. The impact of prolonged lower limb ischemia on amputation, mortality, and functional status: the FRIENDS registry. Am Heart J. 2014;168:577–587.
14.
WyattMFStickrathCShahAet al. Ankle-brachial index performance among internal medicine residents. Vasc Med. 2010;15:99–105.
15.
BellPRCharlesworthDDePalmaRGet al. The definition of critical ischemia of a limb. Working Party of the International Vascular Symposium. Br J Surg. 1982;69:S2
16.
MillsJLSrConteMSArmstrongDGet al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014;59:220–234.e2
17.
RutherfordRBBakerJDErnstCet al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26:517–538.
18.
SetacciCRiccoJBApelqvistJet al. Management of critical limb ischemia and diabetic foot. Clinical practice guidelines of the European Society for Vascular Surgery. Eur J Vasc Endovasc Surg. 2011;42(suppl 2):S1–S90.
19.
DormandyJARutherfordRB.Management of peripheral arterial disease (PAD). TASC Working Group: TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31(1pt 2):S1–S296.
20.
MustaphaJADiaz-SandovalLJAdamsGet al. Lack of association between limb hemodynamics and response to infrapopliteal endovascular therapy in patients with critical limb ischemia. J Invasive Cardiol. 2017;29:175–180.
21.
ShishehborMHHammadTAZetterTet al. An analysis of IN.PACT DEEP randomized trial on the limitations of the societal guidelines-recommended hemodynamic parameters to diagnose critical limb ischemia. J Vasc Surg. 2016;63:1311–1317.
22.
SinghGDArmstrongEJWaldoSWet al. Non-compressible ABIs are associated with an increased risk of major amputation and major adverse cardiovascular events in patients with critical limb ischemia. Vasc Med. 2017;22:210–217.
23.
NakamaTWatanabeNKimuraTet al. Clinical implications of additional pedal artery angioplasty in critical limb ischemia patients with infrapopliteal and pedal artery disease. J Endovasc Ther. 2016;23:83–91.
24.
YamadaTOhtaTIshibashiHet al. Clinical reliability and utility of skin perfusion pressure measurement in ischemic limbs—comparison with other noninvasive diagnostic methods. J Vasc Surg. 2008;47:318–323.
25.
CastronuovoJJAderaHMSmiellJMet al. Skin perfusion pressure measurement is valuable in the diagnosis of critical limb ischemia. J Vasc Surg. 1997;26:629–637.
26.
BunteMCJacobJNudelmanBet al. Validation of the relationship between ankle-brachial and toe-brachial indices and infragenicular arterial patency in critical limb ischemia. Vasc Med. 2015;20:23–29.
27.
BisdasTBorowskiMStavroulakisKet al. Endovascular therapy versus bypass surgery as first-line treatment strategies for critical limb ischemia: results of the interim analysis of the CRITISCH registry. JACC Cardiovasc Interv. 2016;9:2557–2565.
28.
RogersLCAndrosGCaporussoJet al. Toe and flow: essential components and structure of the amputation prevention team. J Vasc Surg. 2010;52(3 suppl):23S–27S.
29.
MiiSTanakaKKyuragiRet al. Aggressive wound care by a multidisciplinary team improves wound healing after infrainguinal bypass in patients with critical limb ischemia. Ann Vasc Surg. 2017;41:196-204.
30.
ChandraVGlebovaNOSalvoNLet al. Partnerships between podiatrists and vascular surgeons in building effective wound care centers. J Am Podiatr Med Assn. 2017;107:471–474.
31.
SumpioBEArmstrongDGLaveryLAet al; Society for Vascular Surgery and American Podiatric Medical Association. The role of interdisciplinary team approach in the management of the diabetic foot: a joint statement from the Society for Vascular Surgery and the American Podiatric Medical Association. J Am Podiatr Med Assoc. 2010;100:309–311.
32.
ChungJModrallJGAhnCet al. Multidisciplinary care improves amputation-free survival in patients with chronic critical limb ischemia. J Vasc Surg. 2015;61:162–169.
33.
HiokiHMiyashitaYMiuraTet al. Prognostic improvement by multidisciplinary therapy in patients with critical limb ischemia. Angiology. 2015;66:187–194.
34.
FarberARosenfieldKMenardM.The BEST-CLI trial: a multidisciplinary effort to assess which therapy is best for patients with critical limb ischemia. Tech Vasc Interv Radiol. 2014;17:221–224.
35.
SmithADHawkinsATSchaumeierMJet al. Predictors of major amputation despite patent bypass grafts. J Vasc Surg. 2016;63:1279–1288.
36.
SimonsJPGoodneyPPNolanBWet al. Failure to achieve clinical improvement despite graft patency in patients undergoing infrainguinal lower extremity bypass for critical limb ischemia. J Vasc Surg. 2010;51:1419–1424.
37.
NevilleRFKayssiA.Development of a limb-preservation program. Blood Purif. 2017;43:218–225.
38.
DriverVRMadsenJGoodmanRA.Reducing amputation rates in patients with diabetes at a military medical center: the limb preservation service model. Diabetes Care. 2005;28:248–253.
39.
KrishnanSNashFBakerNet al. Reduction in diabetic amputations over 11 years in a defined U.K.population: benefits of multidisciplinary team work and continuous prospective audit. Diabetes Care. 2008;31:99–101.
40.
MenardMTFarberAAssmannSFet al. Design and rationale of the best endovascular versus best surgical therapy for patients with critical limb ischemia (BEST-CLI) trial. J Am Heart Assn. 2016;5:e003219.
41.
MustaphaJADiaz-SandovalLJSaabF.Innovations in the endovascular management of critical limb ischemia: retrograde tibiopedal access and advanced percutaneous techniques. Curr Cardiol Rep. 2017;19(8):68.
42.
El-SayedHBennettMELohTMet al. Retrograde pedal access and endovascular revascularization: a safe and effective technique for high-risk patients with complex tibial vessel disease. Ann Vasc Surg. 2016;31:91–98.
43.
WalkerCMMustaphaJZellerTet al. Tibiopedal access for crossing of infrainguinal artery occlusions: a prospective multicenter observational study. J Endovasc Ther. 2016;23:839–846.
44.
MustaphaJAFintonSMDiaz-SandovalLJet al. Percutaneous transluminal angioplasty in patients with infra-popliteal arterial disease: systematic review and meta-analysis. Circ Cardiovasc Interv. 2016;9:e003468.
45.
KatsanosKKitrouPSpiliopoulosSet al. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and Bayesian network meta-analysis of randomized controlled trials. J Endovasc Ther. 2016;23:851–863.
46.
OwensCDGasperWJWalkerJPet al. Safety and feasibility of adjunctive dexamethasone infusion into the adventitia of the femoropopliteal artery following endovascular revascularization. J Vasc Surg. 2014;59:1016–1024.
47.
BosiersMCallaertJKeirseKet al. One-year outcomes of the paclitaxel-eluting, self-expanding Stentys system in the treatment of infrapopliteal lesions in patients with critical limb ischemia. J Endovasc Ther. 2017;24:311–316.
48.
KokkinidisDGArmstrongEJ.Emerging and future therapeutic options for femoropopliteal and infrapopliteal endovascular intervention. Interv Cardiol Clin. 2017;6:279–295.
49.
BrodmannMFroehlichHDorrAet al. Percutaneous transluminal angioplasty versus primary stenting in infrapopliteal arteries in critical limb ischemia. Vasa. 2011;40:482-490.
50.
SpreenMIMartensJMHansenBEet al. Percutaneous transluminal angioplasty and drug-eluting stents for infra-popliteal lesions in critical limb ischemia (PADI) trial. Circ Cardiovasc Interv. 2016;9:e002376.
51.
KabraASureshKVivekanandVet al. Outcomes of angiosome and non-angiosome targeted revascularization in critical lower limb ischemia. J Vasc Surg. 2013;57:44–49.
52.
NevilleRAttingerCBulanEet al. Revascularization of a specific angiosome for limb salvage: does the target artery matter?Ann Vasc Surg. 2009;23:367–373.
53.
SoderstromMAlbackABiancariFet al. Angiosome-targeted infrapopliteal endovascular revascularization for treatment of diabetic foot ulcers. J Vasc Surg. 2013;57:427–435.
54.
ManziMPalenaLM.Retrograde percutaneous transmetatarsal artery access: new approach for extreme revascularization in challenging cases of critical limb ischemia. Cardiovasc Intervent Radiol. 2013;36:554–557.
55.
ManziMFusaroMCeccacciTet al. Clinical results of below-the-knee intervention using pedal-plantar loop technique for the revascularization of foot arteries. J Cardiovasc Surg (Torino). 2009;50:331–337.
56.
NakamaTWatanabeNHaraguchiTet al. Clinical results of pedal arch angioplasty for patients with ischemic wounds. JACC Cardiovasc Interv. 2017;10:79–90.
57.
AdamDJBeardJDClevelandTet al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925–1934.
58.
ChiuKWDaviesRSNightingalePGet al. Review of direct anatomical open surgical management of atherosclerotic aorto-iliac occlusive disease. Eur J Vasc Endovasc Surg. 2010;39:460–471.
59.
MartinDKatzSG.Axillofemoral bypass for aortoiliac occlusive disease. Am J Surg. 2000;180:100–103.
60.
ChangRWGoodneyPPBaekJHet al. Long-term results of combined common femoral endarterectomy and iliac stenting/stent grafting for occlusive disease. J Vasc Surg. 2008;48:362–367.
61.
MaldonadoTSWestinGGJazaeriOet al. Treatment of aortoiliac occlusive disease with the Endologix AFX unibody endograft. Eur J Vasc Endovasc Surg. 2016;52:64–74.
62.
Van HarenEMGoldsteinLJVelasquezOCet al. Endovascular treatment of Transatlantic Inter-Society Consensus D aortoiliac occlusive disease using unibody bifurcated endografts. J Vasc Surg. 2017;65:398–405.
63.
SeegerJMPretusHACarltonLCet al. Potential predictors of outcome in patients with tissue loss who undergo infrainguinal vein bypass grafting. J Vasc Surg. 1999;30:427–435.
64.
VeithFJGuptaSKWengerterKRet al. Short vein grafts in limb-saving arterial reconstructions. J Vasc Interv Radiol. 1990;1:57–61.
65.
KretMRChengDAzarbalAFet al. Utility of direct angiosome revascularization and runoff scores in predicting outcomes in patients undergoing revascularization for critical limb ischemia. J Vasc Surg. 2014;59:121–128.
66.
RzucidloEMWalshDBPowellRJet al. Prediction of early graft failure with intraoperative completion duplex ultrasound scan. J Vasc Surg. 2002;36:975–981.
67.
PereiraCEAlbersMRomitiMet al. Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. J Vasc Surg. 2006;44:510–517.
68.
Comparative evaluation of prosthetic, reversed, and in situ vein bypass grafts in distal popliteal and tibial-peroneal revascularization: Veterans Administration Cooperative Study Group 141. Arch Surg. 1988;123:434–438.
69.
HarrisPLVeithFJShanikGDet al. Prospective randomized comparison of in situ and reversed infrapopliteal vein grafts. Br J Surg. 1993;80:173–176.
70.
WateletJSouryPMenardJFet al. Femoropopliteal bypass: in situ or reversed vein grafts? Ten-year results of a randomized prospective study. Ann Vasc Surg. 1997;11:510–519.
71.
Peinado CebriánJFlores HerreroÁSalgado LopeteguiCLet al. Comparison of bypass with endoscopically harvested internal saphenous vein versus bypass with surgically harvested internal saphenous vein for lower limb arterial disease. Ann Vasc Surg. 2015;29:1353–1362.
72.
VeithFJGuptaSKAscerEet al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg. 1986;3:104–114.
73.
NevilleRFCaponeAAmdurRet al. A comparison of tibial artery bypass performed with heparin-bonded expanded polytetrafluoroethylene and great saphenous vein to treat critical limb ischemia. J Vasc Surg. 2012;56:1008–1014.
74.
MartinRS3rdEdwardsWHMulherinJLJret al. Cryopreserved saphenous vein allografts for below-knee lower extremity revascularization. Ann Surg. 1994;219:664–672.
75.
DosluogluHHO’Brien-IrrMSLukanJet al. Does preferential use of endovascular interventions by vascular surgeons improve limb salvage, control of symptoms, and survival of patients with critical limb ischemia?Am J Surg. 2006;192:572–576.
76.
DarlingJDMcCallumJCSodenPAet al. Predictive ability of the Society for Vascular Surgery wound, ischemia, and foot infection (WiFI) classification system after first-time lower extremity revascularizations. J Vasc Surg. 2017;65:695–704.
77.
DarlingJDMcCallumJCSodenPAet al. Predictive ability of the Society for Vascular Surgery wound, ischemia, and foot infection (WiFI) classification system following infra-popliteal endovascular interventions for critical limb ischemia. J Vasc Surg. 2016;64:616–622.
78.
CullDLManosGHartleyMCet al. An early validation of the Society for Vascular Surgery lower extremity threatened limb classification system. J Vasc Surg. 2014;60:1535–1541.
79.
SogaYIidaOTakaharaMet al. Two-year life expectancy in patients with critical limb ischemia. JACC Cardiovasc Interv. 2014;7:1444–1449.
80.
AboyansVCriquiMHAbrahamPet al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. 2012;126:2890–2909.
81.
ReedGWYoungLBaghIet al. Hemodynamic assessment before and after endovascular therapy for critical limb ischemia and association with clinical outcomes. JACC Cardiovasc Interv. 2017;10:2451–2457.
82.
UtsunomiyaMNakamuraMNagashimaYet al. Predictive value of skin perfusion pressure after endovascular therapy for wound healing in critical limb ischemia. J Endovasc Ther. 2014;21:662–670.
83.
UtsunomiyaMNakamuraMNakanishiMet al. Impact of wound blush as an angiographic end point of endovascular therapy for patients with critical limb ischemia. J Vasc Surg. 2012;55:113–121.
84.
Montero-BakerMFAu-YeungKYWisniewskiNAet al. The first in man “Si se puede” study for the use of micro-oxygen sensors (MOXYs) to determine dynamic relative oxygen indices in the feet of patients with limb-threatening ischemia during endovascular therapy. J Vasc Surg. 2015;61:1501–1509.
85.
LeeMSRhaSWHanSKet al. Clinical outcomes of patients with critical limb ischemia who undergo routine coronary angiography and subsequent percutaneous coronary intervention. J Invasive Cardiol. 2015;27:213–217.
86.
SchanzerAHeveloneNOwensCDet al. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg. 2008;47:774–781.
87.
Aiello FrancescoAKhanAMeltzerAet al. Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia. J Vasc Surg. 2012;55:371–380.
88.
RamoOJJuhaLMarttiSet al. Effects of lovastatin in prevention of restenosis after percutaneous transluminal angioplasty in lower limbs. Int J Angiol. 1995;4:173–176.
89.
SetacciCRiccoJB; European Society for Vascular Surgery. Guidelines for critical limb ischaemia and diabetic foot—introduction. Eur J Vasc Endovasc Surg. 2011;42(suppl 2):S1–S3.
90.
NorgrenLPatelMRHiattWRet al. Outcomes of patients with critical limb ischaemia in the EUCLID trial. Eur J Vasc Endovasc Surg. 2018;55:109–117.
91.
HiattWRFowkesFGHeizerGet al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376:32–40.
92.
SodenPAZettervallSLUlteeKHet al. Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization. J Vasc Surg. 2016;64:1633–1644.
93.
ArmstrongEJAndersonDRYeoKKet al. Association of dual antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg. 2015;62:157–165.
94.
BonacaMPGutierrezJACreagerMAet al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease. Circulation. 2016;133:997–1005.
95.
AnandSSBoschJEikelboomJWet al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial. Lancet. 2018;391:219–229.
96.
CarterAMurphyMOHalkaATet al. The natural history of stenoses within lower limb arterial bypass grafts using a graft surveillance program. Ann Vasc Surg. 2007;21:695–703.
